Bloom Burton Cuts Earnings Estimates for Microbix Biosystems

Microbix Biosystems Inc. (TSE:MBX) – Research analysts at Bloom Burton cut their FY2027 earnings per share (EPS) estimates for shares of Microbix Biosystems in a research report issued on Friday, May 16th. Bloom Burton analyst D. Martin now forecasts that the company will post earnings of $0.04 per share for the year, down from their previous forecast of $0.05. The consensus estimate for Microbix Biosystems’ current full-year earnings is $0.02 per share.

Microbix Biosystems Price Performance

Shares of MBX opened at C$0.35 on Monday. The company has a debt-to-equity ratio of 22.61, a quick ratio of 5.57 and a current ratio of 7.15. The stock has a 50 day simple moving average of C$0.38 and a 200 day simple moving average of C$0.39. Microbix Biosystems has a 52-week low of C$0.29 and a 52-week high of C$0.55. The firm has a market capitalization of C$46.10 million, a PE ratio of 13.33 and a beta of 0.34.

Insider Activity at Microbix Biosystems

In other Microbix Biosystems news, Senior Officer Mark Adrian Luscher sold 70,750 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of C$0.43, for a total transaction of C$30,295.15. 14.00% of the stock is owned by insiders.

Microbix Biosystems Company Profile

Microbix Biosystems Inc, a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products.